SLC5A2 and type 2 diabetes mellitus: <b>Background/Objectives:</b> Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide well-established cardiovascular and renal benefits in heart failure (HF), type 2 diabetes (T2DM), and chronic kidney disease (CKD).